126 related articles for article (PubMed ID: 1459730)
1. Growth of Hodgkin cell lines in severely combined immunodeficient mice.
von Kalle C; Wolf J; Becker A; Sckaer A; Munck M; Engert A; Kapp U; Fonatsch C; Komitowski D; Feaux de Lacroix W
Int J Cancer; 1992 Dec; 52(6):887-91. PubMed ID: 1459730
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
Kapp U; Wolf J; von Kalle C; Tawadros S; Röttgen A; Engert A; Fonatsch C; Stein H; Diehl V
Ann Oncol; 1992 Sep; 3 Suppl 4():21-3. PubMed ID: 1450076
[TBL] [Abstract][Full Text] [Related]
3. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
Kapp U; Düx A; Schell-Frederick E; Banik N; Hummel M; Mücke S; Fonatsch C; Bullerdiek J; Gottstein C; Engert A
Ann Oncol; 1994; 5 Suppl 1():121-6. PubMed ID: 7513537
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice.
Kapp U; Wolf J; Hummel M; Pawlita M; von Kalle C; Dallenbach F; Schwonzen M; Krueger GR; Müller-Lantzsch N; Fonatsch C
Blood; 1993 Aug; 82(4):1247-56. PubMed ID: 8353287
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
Bargou RC; Mapara MY; Zugck C; Daniel PT; Pawlita M; Döhner H; Dörken B
J Exp Med; 1993 May; 177(5):1257-68. PubMed ID: 8386741
[TBL] [Abstract][Full Text] [Related]
6. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice.
Dewan MZ; Watanabe M; Ahmed S; Terashima K; Horiuchi S; Sata T; Honda M; Ito M; Watanabe T; Horie R; Yamamoto N
Cancer Sci; 2005 Aug; 96(8):466-73. PubMed ID: 16108827
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications.
Diehl V; Pfreundschuh M; Fonatsch C; Stein H; Falk M; Burrichter H; Schaadt M
Cancer Surv; 1985; 4(2):399-419. PubMed ID: 3842319
[TBL] [Abstract][Full Text] [Related]
9. Cellular protein profiles of the Hodgkin's disease cell lines L428, KM-H2 and HDLM-2: a comparative study.
Hock BD; Hart DN
Leuk Res; 1992; 16(3):253-63. PubMed ID: 1560674
[TBL] [Abstract][Full Text] [Related]
10. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines.
Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):1-25. PubMed ID: 7682880
[TBL] [Abstract][Full Text] [Related]
11. Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice.
Walter J; Möller P; Moldenhauer G; Schirrmacher V; Pawlita M; Wolf J
Int J Cancer; 1992 Jan; 50(2):265-73. PubMed ID: 1309726
[TBL] [Abstract][Full Text] [Related]
12. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's disease derived cell lines: a review.
Drexler HG; Minowada J
Hum Cell; 1992 Mar; 5(1):42-53. PubMed ID: 1419951
[TBL] [Abstract][Full Text] [Related]
14. New immunodeficient mouse strains bred by introducing beige and xid mutations into the KSN nude strain.
Ishigaki Y; Hayakawa J; Hashimoto N; Nikaido H; Nikaido O
Lab Anim Sci; 1996 Aug; 46(4):418-24. PubMed ID: 8872993
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's disease cell lines: a model for interleukin-1-independent accessory cell function.
McKenzie JL; Egner W; Calder VL; Hart DN
Immunology; 1992 Nov; 77(3):345-53. PubMed ID: 1478681
[TBL] [Abstract][Full Text] [Related]
16. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
18. The Reed-Sternberg cell/lymphocyte rosette. I. Properties of rosettes formed between Hodgkin's cell lines and allogeneic lymphocytes.
Flavell DJ; Wright DH
Br J Cancer; 1989 Feb; 59(2):165-73. PubMed ID: 2495015
[TBL] [Abstract][Full Text] [Related]
19. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.
Kapp U; Yeh WC; Patterson B; Elia AJ; Kägi D; Ho A; Hessel A; Tipsword M; Williams A; Mirtsos C; Itie A; Moyle M; Mak TW
J Exp Med; 1999 Jun; 189(12):1939-46. PubMed ID: 10377189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
